Answers are grounded in this paper and cite their sources.
, which encodes serum and glucocorticoid-regulated kinase 1, is also significantly elevated in PFC of patients with AD. Administration of a specific Sgk1 inhibitor reduces hyperphosphorylated tau protein, restores PFC glutamatergic synaptic function, and ameliorates memory deficits in AD mice. These results have found a novel epigenetic mechanism and a potential therapeutic strategy for AD and related neurodegenerative disorders.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: